First National Bank of Omaha Purchases 13,867 Shares of Quest Diagnostics Incorporated $DGX

First National Bank of Omaha lifted its position in shares of Quest Diagnostics Incorporated (NYSE:DGX) by 29.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 60,199 shares of the medical research company’s stock after acquiring an additional 13,867 shares during the period. First National Bank of Omaha’s holdings in Quest Diagnostics were worth $10,461,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Paradiem LLC bought a new position in shares of Quest Diagnostics in the fourth quarter worth about $13,652,000. Union Bancaire Privee UBP SA bought a new position in shares of Quest Diagnostics in the fourth quarter worth about $1,517,000. Cibc World Market Inc. lifted its holdings in shares of Quest Diagnostics by 209.6% in the third quarter. Cibc World Market Inc. now owns 7,765 shares of the medical research company’s stock worth $1,480,000 after acquiring an additional 5,257 shares during the last quarter. Assenagon Asset Management S.A. lifted its holdings in shares of Quest Diagnostics by 346.5% in the fourth quarter. Assenagon Asset Management S.A. now owns 24,949 shares of the medical research company’s stock worth $4,329,000 after acquiring an additional 19,361 shares during the last quarter. Finally, ANTIPODES PARTNERS Ltd lifted its holdings in shares of Quest Diagnostics by 6,070.7% in the third quarter. ANTIPODES PARTNERS Ltd now owns 61,707 shares of the medical research company’s stock worth $11,761,000 after acquiring an additional 60,707 shares during the last quarter. Institutional investors own 88.06% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the stock. Barclays increased their target price on shares of Quest Diagnostics from $225.00 to $230.00 and gave the stock an “overweight” rating in a report on Wednesday, April 22nd. Wall Street Zen cut shares of Quest Diagnostics from a “buy” rating to a “hold” rating in a report on Saturday, May 30th. Jefferies Financial Group reissued a “buy” rating and issued a $225.00 target price on shares of Quest Diagnostics in a report on Tuesday, April 21st. Evercore set a $225.00 target price on shares of Quest Diagnostics in a report on Tuesday, April 21st. Finally, Truist Financial increased their target price on shares of Quest Diagnostics from $220.00 to $225.00 and gave the stock a “hold” rating in a report on Wednesday, April 22nd. Seven analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the stock. According to MarketBeat.com, Quest Diagnostics has an average rating of “Moderate Buy” and a consensus target price of $216.58.

Quest Diagnostics Stock Performance

Quest Diagnostics stock opened at $202.62 on Friday. The business has a 50 day moving average of $194.99 and a 200-day moving average of $191.86. Quest Diagnostics Incorporated has a 1 year low of $164.65 and a 1 year high of $213.50. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.18 and a quick ratio of 1.08. The company has a market capitalization of $22.43 billion, a P/E ratio of 22.39, a P/E/G ratio of 2.43 and a beta of 0.59.

Quest Diagnostics (NYSE:DGX) last released its quarterly earnings data on Tuesday, April 21st. The medical research company reported $2.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.37 by $0.13. The company had revenue of $2.90 billion during the quarter, compared to the consensus estimate of $2.83 billion. Quest Diagnostics had a return on equity of 15.60% and a net margin of 9.07%.The firm’s revenue was up 9.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.94 earnings per share. Quest Diagnostics has set its FY 2026 guidance at 10.630-10.830 EPS. On average, equities research analysts predict that Quest Diagnostics Incorporated will post 10.72 earnings per share for the current year.

Quest Diagnostics Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, July 22nd. Shareholders of record on Wednesday, July 8th will be given a dividend of $0.86 per share. This represents a $3.44 dividend on an annualized basis and a yield of 1.7%. The ex-dividend date of this dividend is Wednesday, July 8th. Quest Diagnostics’s dividend payout ratio is currently 38.01%.

Insider Buying and Selling

In other Quest Diagnostics news, CEO J. E. Davis sold 10,000 shares of the stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $194.14, for a total transaction of $1,941,400.00. Following the completion of the sale, the chief executive officer owned 132,423 shares of the company’s stock, valued at approximately $25,708,601.22. This represents a 7.02% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Karthik Kuppusamy sold 8,147 shares of the stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $200.00, for a total transaction of $1,629,400.00. Following the sale, the senior vice president directly owned 13,510 shares of the company’s stock, valued at $2,702,000. This represents a 37.62% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 0.88% of the company’s stock.

Quest Diagnostics Profile

Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.

Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.